After a very strong 5 year run, Cardinal Health’s stock now faces a valuation question, with a low overall value score and recent checks framing it as expensive on earnings based measures even as the share price reflects growing confidence in its home care and medical distribution businesses.

• Cardinal Health has returned about 320% over the past 5 years, which puts extra focus on whether the current price still leaves much room for further share price gains.
• Recent acquisitions in at home diabetes and urology supplies can support expectations for growth, while the pace, integration and execution of these deals may add risk if they do not translate into the cash flows investors are expecting.
• The stock passes only 2 of 6 valuation checks on Simply Wall St’s framework, which leans toward Cardinal Health not being a clear bargain at current levels even after its strong track record of returns (2/6 valuation score).

The issue now is whether Cardinal Health’s recent share price strength has moved the stock ahead of what its current valuation can justify.

Does Cardinal Health Look Pricey on Earnings?

P/E is a useful lens for Cardinal Health because earnings remain a key reference point for many investors in large, established healthcare distributors. Cardinal Health currently trades on a P/E of about 34.0x, compared with an average of roughly 27.5x for direct peers and 25.5x across the broader Healthcare industry. That places the stock at a clear premium to both its closest comparison group and the sector overall.

On Simply Wall St’s model, a more tailored fair P/E for Cardinal Health, given its profile and risks, sits nearer 29.1x. Against that benchmark, the current multiple still appears elevated, which suggests investors may be paying a higher price for the company’s recent momentum and growth initiatives in home care and medical distribution. Despite the recent acquisitions in diabetes and urology supplies lifting interest in Cardinal Health, the present P/E already reflects a relatively optimistic view compared with peers.

Overall, Cardinal Health stock currently appears expensive on its P/E multiple relative to both this indicative fair ratio and the cited sector benchmarks.

The Cardinal Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Cardinal Health pick up where this valuation puzzle leaves off by spelling out which combinations of future growth, margins and earnings would need to play out for Cardinal Health's stock to be worth materially more or less than it is today on the Community page. Each narrative links its implied number to a specific view on how Cardinal Health's growth, profitability and risk profile might evolve, giving you a reference point you can come back to as new information appears.

Share your own Simply Wall St Narrative on Cardinal Health to put a number-driven view on whether moves like the Strive Medical and AdaptHealth diabetes acquisitions deliver what you expect.

It is a way to set out your case in public and then see, over time, how your assumptions on Cardinal Health's growth, margins and execution stack up against the results.

Do you think there's more to the story for Cardinal Health? Head over to our Community to see what others are saying!

The Bottom Line

For Cardinal Health, the current picture leans toward overvalued on market multiples, with the share price already baking in a confident view on its earnings power and expansion in home care related areas. The low overall value score reinforces that this is not a clear-cut bargain and that expectations are doing a lot of the work. From here, the key question is whether Cardinal Health can turn its recent acquisitions and broader execution into the kind of earnings and margin profile that keeps investors comfortable paying this premium rather than seeing the multiple settle closer to peers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.